Your session is about to expire
← Back to Search
Targeted Drug Therapy for Pancreatic Cancer
Study Summary
This trial is exploring how four different drugs work in patients with pancreatic cancer.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a condition that affects my ability to swallow or absorb pills.I am not pregnant or breastfeeding.I am not taking strong or moderate drugs that affect liver enzymes.My health conditions make surgery too risky according to hospital standards.I don't have lasting side effects from past treatments, except for possible mild nerve issues, hair loss, or skin color changes.My cancer can potentially be cured with surgery.I have not had major surgery in the last 4 weeks or minor surgery in the last 2 weeks.I agree to use birth control as required by the OLAPARIB study.I have previously been treated with a PLK1 inhibitor for my condition.I do not have an ongoing serious infection that isn't getting better with treatment.My tumor cannot be biopsied with a core needle.I am willing and able to follow the study's treatment and visit schedule.I do not have serious heart disease or poor heart function.I am not taking strong or moderate drugs that affect liver enzymes.I can take care of myself and am up and about more than half of my waking hours.My kidney function is within the required range.My hemoglobin level is at least 9.0 g/dL without recent blood transfusions.I have pancreatic cancer and if treated before, I've had a 10-day break from my last therapy.I am 18 years old or older.I am willing to have tumor biopsies during the study.I can swallow pills without any issues.I have never been treated with a WEE1 inhibitor.I don't have lasting side effects from previous treatments, except for mild neuropathy, hair loss, or skin color changes.I have a tumor that can be safely biopsied according to hospital rules.I have no cancer history, except for certain skin, breast, or cervical cancers treated over 6 months ago.I don't have a personal or family history of long QT syndrome or Torsade de Pointes.I am not using strong CYP3A4/UGT1A1 inhibitors or inducers, or I can switch to another therapy.I am not taking any medications that increase the risk of heart rhythm problems, or if I am, I'm monitored closely.I don't have active hepatitis B, may have treated hepatitis C, and if I have HIV, it's well-managed.I am not eligible for cobimetinib due to specific criteria.My kidney function, measured by creatinine clearance, is within or above the normal range.I am not allergic to drugs similar to ZN-c3.I am not using other cancer treatments or strong medications that affect enzymes while on the study drug.My pancreatic cancer is confirmed and can be surgically removed or has spread.
- Group 1: Arm II (cobimetinib)
- Group 2: Arm IV (onvansertib)
- Group 3: Arm I (olaparib)
- Group 4: Arm V (azenosertib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still available slots in this clinical research endeavor?
"That's correct. The details published on clinicaltrials.gov confirm that this investigation is currently enrolling participants, having been posted in August 2019 and last updated in October 2022. 80 patients will be required to join from a single site."
Is eligibility for this trial confined to those under 40 or are older individuals accepted as well?
"This trial is suitable for individuals aged between 18 to 78. Conversely, 33 trials are available for minors and 1481 options are offered for seniors."
What other investigations have transpired concerning Cobimetinib?
"Currently, there are 235 active trials for cobimetinib with 30 of those in phase 3. These studies span 10365 locations across the globe and a particularly high concentration can be found around Houston, Texas."
What is the upper limit to participant recruitment for this trial?
"Affirmative. The information on clinicaltrials.gov states that this experiment is actively seeking volunteers, with an initial post date of August 1st 2019 and most recent update occurring October 31st 2022. 80 enrollees are needed from a single location."
Am I eligible to join this clinical investigation?
"This medical trial has 80 enrollees, aged between 18 and 78 who have been diagnosed with stage iib pancreatic cancer ajcc v8. Furthermore, applicants need to be either treatment-naïve or have completed prior therapy for PDAC (Pancreatic Ductal Adenocarcinoma) at least ten days ago. Imaging must show one lesion that can be biopsied according to institutional standards; though this criterion may be waived depending on individual circumstances. Lastly, the Eastern Cooperative Oncology Group's performance rating of 0-2 is mandatory."
Has this type of research previously been conducted?
"Currently, there are 235 independent clinical trials actively investigating cobimitinib spanning 61 nations and 1524 cities. The initial experiment was run in 2005 by AstraZeneca with 98 patients taking part and has since been followed up by 94 separate studies. It achieved stage 1 of the drug approval process that year."
What medical conditions does Cobimetinib typically ameliorate?
"Cobimetinib is frequently prescribed for advaced medical directives. It can also provide relief from malignant neoplasm of ovary, primary peritoneal cancer, hallucinations, and somatic conditions."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger